Randomization Group  
  Overall ‘Abacavir group’ ‘Tenofovir Group’ P-value*
Total Sample, number 27 13 14  
Age, median (IQR) years 46 [41, 53] 47 [43, 53] 42.5 [32, 52] 0.30
Male Gender, # (%) 26 (96.3%) 12 (92.3%) 14 (100.0%) 0.30
Race/Ethnicity, # (%)       0.36
White 22 (81.5%) 10 (76.9%) 12 (85.7%)  
African American 4 (14.8%) 3 (23.1%) 1 (7.1%)  
Hispanic 0 (0.0%) 0 (0.0%) 0 (0.0%)  
Other 1 (3.7%) 0 (0.0%) 1 (7.1%)  
IDU, # (%)       0.13
Prior 2 (7) 2 (15) 0 (0)  
Never 25 (93) 11 (85) 14 (100)  
Hep B or C positive, # (%) 3 (11) 2 (15) 1 (7) 0.30
Current Smoker, # (%) 6 (22) 3 (23) 3 (21) 0.92
Blood pressure lowering therapy, # (%) 4 (16) 4 (31) 0 (0) 0.10
Lipid lowering therapy, # (%) 6 (23) 3 (23) 3 (23) >0.99
Tot. Chol., median (IQR) mg/dL 201 (178, 238) 205 (185, 214) 189 (178, 243) 0.75
LDL-C, median (IQR) mg/dL 107 (91, 127) 100 (93, 127) 108 (91, 126) 0.81
HDL-C, median (IQR) mg/dL 43 (36, 55) 42 (36, 48) 49 (36, 59) 0.27
Framingham Risk Score, median (IQR) % coronary event over 10yrs 6.0 (3.6, 10.4) 8.5 (5.6, 12.8) 4.7 (2.3, 7.9) 0.052
Biomarkers        
hsCRP, median (IQR) μg/mL 2.1 (0.9, 3.2) 2.1 (1.2, 2.8) 2.3 (0.9, 3.2) 0.78
IL-6, median (IQR) pg/mL 1.7 (1.2, 2.3) 1.7 (1.5, 2.2) 2.1 (1.0, 2.3) 0.78
D-dimer, median (IQR) μg/mL 0.2 (0.1, 0.2) 0.2 (0.1, 0.5) 0.1 (0.1, 0.2) 0.02
ADMA, median (IQR) μmol/L 0.6 (0.5, 0.7) 0.6 (0.5, 0.7) 0.6 (0.5, 0.8) 0.47
sICAM-1, median (IQR) ng/mL 228 (184, 274) 228 (172, 274) 227 (190, 253) 0.98
vWF, median (IQR) % 122 (108, 153) 133 (110, 183) 120 (108, 133) 0.34
sTM, median (IQR) pg/mL 4944 (4145, 5945) 5382 (4096, 5945) 4882 (4567, 5561) 0.94
* P-values are from comparisons between groups, using Wilcoxon or Chi-square as appropriate.
Table 1: Baseline Characteristics.
Goto home»